DUPIXENT was studied in the largest clinical trial program to date for CRSwNP: 724 total participants; SINUS-24: 276, Trial 2: 448, Combined: 724. Adults (≥18 years) on background INCS^a with CRSwNP were included despite prior sino-nasal surgery or prior treatment with, or who were ineligible to receive or were intolerant to, systemic corticosteroids in the past 2 years were enrolled in the clinical trials.

In both SINUS-24 and SINUS-52, 73% to 90% of subjects had opacification of all sinuses. Prior surgery patients had a mean of 2.0 prior surgeries, and SCS use patients had 1.6 SCS courses in the previous 2 years. ~79% of patients enrolled in both trials had atopic diseases. 60% of patients had history of asthma, and 27% had NSAID-ERD.

Patients with chronic rhinosinusitis without nasal polyposis were not included in these trials. Rescue with systemic corticosteroids or surgery was allowed at investigators’ discretion. The total population of patients in SINUS-24 and SINUS-52 was unrestricted by minimum baseline blood eosinophil count.¹

^a All patients in the placebo and DUPIXENT arms were on a background therapy of INCS, mometasone furoate nasal spray.⁸

CRSwNP, chronic rhinosinusitis with nasal polyposis; INCS, intranasal corticosteroid; SCS, systemic corticosteroid; NSAID-ERD, nonsteroidal anti-inflammatory drug-exacerbated respiratory disease.

view the study designs